From the publishers of JADPRO
HR+ HER2- Breast Cancer
Resource Center
Menu
Resources
Videos
Videos
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge on first-line treatment for metastatic ER+ HER2- breast cancer
Last Updated: Monday, October 14, 2024
Loading...
Advertisement
News & Literature Highlights
Radiographics
Breast cancer surveillance in patients with a personal history of breast cancer: Updates and controversies
Frontiers in Oncology
Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: Updated systematic review
Journal of Clinical Oncology
Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
Seminars in Nuclear Medicine
AI in breast cancer imaging: An update and future trends
The Breast
Awareness of genomic testing among patients with breast cancer in Europe
BMC Women’s Health
Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis
npj Precision Oncology
Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling
Cancer Treatment Reviews
First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?
European Journal of Nuclear Medicine and Molecular Imaging
Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors
Chinese Journal of Cancer Research
Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns
Advertisement
Case Studies
Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer
First-Line Treatment for Metastatic ER+ HER2- Breast Cancer
Advertisement
Quizzes
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer
Test your knowledge on HR-positive, HER2-negative breast cancer
Test your knowledge on first-line treatment for metastatic ER+ HER2- breast cancer